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Purpose: To describe a complication of retrobulbar amphotericin B injections in the treatment of invasive
rhino-orbital asperigillosis.
Observations: 27 year-old renal transplant recipient presented with a two-week history of headache,
binocular diplopia and proptosis of the left eye. Endonasal biopsy on hospital day 3 conﬁrmed the
diagnosis of rhino-orbital invasive Aspergillus fumigatus involving the left orbital apex.
In addition to systemic antifungal treatment and cessation of immunosuppression, retrobulbar
amphotericin B injections (3.5 mg/1 ml) combined with endoscopic local debridement were initiated
when the patient developed progressive visual loss. Retrobulbar injections were administered on hos-
pital days 8, 10, 14, 17, and 20. Endoscopic debridement occurred on hospital days 10 and 16.
After the ﬁfth retrobulbar amphotericin B injection, the patient developed acute orbital compartment
syndrome with intraocular pressures ranging from 47 to 86 mmHg and vision declined to 20/200,
requiring emergent lateral canthotomy and superior and inferior cantholysis. Close observation without
further intervention resulted in return of vision to 20/20 and normalization of intraocular pressure.
Conclusion and importance: Retrobulbar amphotericin B in combination with local debridement may be
considered an alternative to exenteration for invasive aspergillosis secondary to reversible immuno-
suppression. To the authors' knowledge, orbital compartment syndrome secondary to retrobulbar
amphotericin B administration has not previously been reported. Patients should be counseled on the
risk of severe local inﬂammation due to amphotericin B. More research is needed to establish the most
appropriate dosing, frequency, and duration of retrobulbar amphotericin B injections in the treatment of
life-threatening Aspergillus infections.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Considerable debate surrounds the management of invasive
sino-orbital fungal infections: when orbital tissue is involved
certain authors advocate exenteration, where as others report
positive outcomes following globe-sparing procedures [1e3].
Although rarely published, retrobulbar amphotericin B injection
has been described as a viable globe-sparing technique in the
management of orbital aspergillosis [3e6]. Herein, the authors
report a case of an immunocompromised patient who received
repeat amphotericin B retrobulbar injections for sino-orbital
aspergillosis. Despite a successful long-term outcome, retrobulbaro, CA, 94143, USA.
rsten).
access article under the CC BY-NCamphotericin B induced an acute orbital compartment syndrome,
requiring urgent intervention. To the authors' knowledge, this is the
ﬁrst documented case of orbital compartment syndrome subse-
quent to retrobulbar amphotericin B.
The Review Board at our institution ruled that approval was not
required for this study. All patient information was handled in
compliance with the Health Insurance Portability and Account-
ability Act (HIPAA) and research adhered to the tenets of the
Declaration of Helsinki. Additionally patient consent for publication
was obtained per University of California San Francisco guidelines.2. Case report
A 27 year-old African American male was admitted for severe
left-sided headache and diplopia. The patient's past medical history-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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glomerulosclerosis, for which he was on prednisone, mycopheno-
late mofetil and belatacept.
Ophthalmologic examination revealed visual acuity (VA) of 20/
20 in both eyes, left upper lid ptosis and severe generalized re-
striction of extraocular movements in the left eye (Fig. 1A). Pupil-
lary reﬂexes, intraocular pressure (IOP), corneal sensation, slit lamp
exam and fundus exam including optic disks were normal in both
eyes. Although rigid nasal endoscopy was normal at the time of
admission, Brain MRI with contrast revealed focal soft tissue
enhancement at the left orbital apex with a low diffusion coefﬁ-
cient (Fig. 1B). Presuming a diagnosis of invasive fungal infection,
immunosuppression was discontinued and the patient was
empirically placed on intravenous antifungal therapy.
On hospital day 2 the patient underwent left maxillary antros-
tomy, total ethmoidectomy, concha bullosa resection and sphe-
noidotomy with necrotic tissue and hyphae removed from the
sphenoid sinus. Pathology specimens from the procedure were
consistent with Aspergillus and therapy was narrowed to intrave-
nous Voriconazole and Caspofungin.
VA remained stable at 20/25 OU, however the patient gradually
developed increased proptosis of the left eye with an associated
afferent pupillary defect. Repeat MRI revealed disease progression
at the orbital apex. Out of reluctance to undergo aggressive orbital
debridement in a patient with normal VA, it was elected on day 8 to
proceed with a retrobulbar injection of amphotericin B for the left
eye. One milliliter (ml) of 3 mg/ml (mg/ml) amphotericin B with
antecedent retrobulbar injection of 1:1 2% lidocaine, 0.5% Marcaine
was performed without incident. On hospital day 10, the patient
underwent endoscopic orbital decompression with resection of
necrotic material at the orbital apex and repeat retrobulbar injec-
tion of amphotericin B (1 ml of 3.5 mg/ml) while under general
anesthesia. The patient's clinical course continued towax andwane
with VA deteriorating to 20/70 at its nadir.
Retrobulbar amphotericin B (1 ml of 3.5 mg/ml) injection was
repeated on days 14, 17, and 20. On the morning of day 21, the
patient developed rapid-onset proptosis of the left eye (Fig. 2A).
Bedside examination of the left eye documented VA 20/200,Fig. 1. A) Patient photo on presentation showing ptosis and exotropia of the left eye B) MR
(arrow).complete external ophthalmoplegia and intraocular pressure as
measured by Tonopen (Medtronic, Minneapolis, MN) consistently
at or above 47 mmHg. Acute orbital compartment syndrome was
diagnosed and canthotomywith cantholysis of the upper and lower
eyelids was performed. Intraocular pressure immediately fell to
31 mmHg. Urgent MRI revealed diffuse edema of retrobulbar fat
inducing proptosis and optic nerve stretch, and the imaging did not
support extension of the infection (Fig. 2B). Twenty-four hours
following canthotomy/cantholysis VA returned to 20/25 in the left
eye.
Given signiﬁcant improvement in proptosis and stability of
vision, the patient was discharged on hospital day 23 with intra-
venous systemic antifungals administered by home nursing. Two
weeks after discharge, aside from limitation in depression OS, the
patient's ophthalmologic exam was within normal limits in both
eyes. Two years following discharge, although VA and ophthalmic
exam were unchanged (Fig. 3), the patient's cadaveric transplant
eventually failed as a result of discontinuation of immunosup-
pression and he is currently on dialysis awaiting repeat renal
transplantation.
3. Discussion
No evidence-based consensus exists for the management of
invasive sino-orbital fungal infections. Although nearly all patients
receive intravenous antifungals plus endoscopic sinus debride-
ment, the treatment of orbital disease remains controversial and
can range from globe-sparing to radical exenteration [1e3]. To date,
the most frequently reported globe-sparing therapy has been local
irrigation of amphotericin B via a catheter or drain, with or without
conservative orbital debridement [7,8].
To our knowledge, only four previously published cases of sino-
orbital aspergillosis have employed retrobulbar injections of
amphotericin B [3e6]. In these reports, the quantity of amphoter-
icin B administered ranged from 1 to 5.25 mg every 2e7 days. In all
four cases, retrobulbar injections were without complication and
VA was maintained or improved. However, in two cases patients
eventually succumbed to systemic infection [4,5].I on presentation demonstraing focal soft tissue enhancement at the left orbital apex
Fig. 2. A) Patient on day 21 with acute increase in proptosis and chemosis of the left eye. B) MRI on day 21 demonstrating orbital soft tissue edema around the left eye and optic
nerve stretch with tenting of the left globe.
Fig. 3. Patient at two year follow-up with complete resolution of proptosis of the left
eye.
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sterols, causing leakage of intracellular electrolytes and derange-
ment of metabolic activity [9]. Given that both yeast and human
cell-membranes contain sterols, the medication is toxic to both
pathogen and host. Although systemic side effects such as fever,
bone marrow suppression and renal toxicity are well documented,
amphotericin B is also locally cytotoxic [9,10]. In vitro mouse os-
teoblasts and ﬁbroblasts studies have shown that exposure to
amphotericin B concentrations beyond 100 mg/ml for greater than
1 h causes widespread cell death [10]. Intra-articular amphotericin
B injection can cause synovitis and, in rare instances, subcutaneous
amphotericin B injection has induced acute soft-tissue edema
[11e13].
It is not clear why our patient developed acute orbital
compartment syndrome subsequent to his ﬁfth retrobulbar injec-
tion. Each injected vial was prepared in the exact same fashion and
was buffered, as required by the medication package insert, with
sterile water and 5% dextrose [14]. Intravenous amphortericin B has
an initial plasma half-life of 24 h, followed by an elimination half-
life of 15 days [14]. Our patient had normal creatinine clearance
at the time of the orbital compartment syndrome. Additionally,
review of his other medications did not suggest any cross reactivity
that would account for an increased inﬂammatory response to
amphotericin B or that would affect amphotericin B metabolism.
The rate of amphotericin B elimination from the normal human
orbit is unknown. Because aspergillosis causes ischemic vasculitis,
it is likely that arterial perfusion and venous return within our
patient's orbit were grossly diminished. We hypothesize that witheach successive injection of amphotericin B, intraorbital concen-
tration increased until a massively cytotoxic quantity was reached,
possibly precipitating the compartment syndrome.
4. Conclusion
Retrobulbar amphotericin B injection is an infrequently re-
ported globe-sparing technique that can aid in the management of
invasive sino-orbital aspergillosis. To our knowledge, this is the ﬁrst
documented case of acute orbital compartment syndrome subse-
quent to retrobulbar injection of amphotericin B. Although our
patient had an excellent long-term outcome, physicians attempting
retrobulbar injection of amphotericin B should be aware of this
potentially urgent complication.
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